In 229 children under 18 with venous thromboembolism, weight-tiered apixaban vs standard of care gave similar recurrent VTE or VTE-related death (2·6% vs 2·7%) and clinically relevant bleeding (1·3% vs 1·4%) in this descriptive randomised trial; no major bleeding.
RCTn = 229
Brandão et al. Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial